The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.
 
Suheil Albert Atallah-Yunes
No Relationships to Disclose
 
Matthew J. Rees
No Relationships to Disclose
 
Thomas E. Witzig
Honoraria - Curio Science (Inst)
Consulting or Advisory Role - Salarius Pharmaceuticals; Tornado Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - BeiGene; Incyte; Loxo/Lilly; MorphoSys; Seagen; Tessa Therapeutics
 
Ellen D McPhail
No Relationships to Disclose
 
Javier Munoz
Honoraria - Curio Science; Kyowa Hakko Kirin; OncView; Physicans' Education Resource; Seagen; Targeted Oncology
Consulting or Advisory Role - ADC Therapeutics; Alexion Pharmaceuticals; Aurobindo; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Fosun Kite; Genentech; Genmab; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Seagen; Secura Bio; SERVIER; TG Therapeutics; Zodiac Pharma
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Madiha Iqbal
No Relationships to Disclose
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)